NeuroSense Reports Breakthrough 65% Reduction in ALS Mortality Risk with PrimeC

NeuroSense Therapeutics Ltd. announced breakthrough clinical data for its lead drug candidate, PrimeC, aimed at treating Amyotrophic Lateral Sclerosis (ALS). The latest results revealed a statistically significant 65% reduction in the risk of death for patients using the drug compared to control groups. Furthermore, PrimeC demonstrated a median survival benefit exceeding 14 months, representing a major milestone in the treatment of this fatal neurodegenerative disease. These findings, announced on February 18, 2026, serve as a critical catalyst for the company's clinical development path. Market analysts expect the positive clinical outcome to drive significant investor interest in the biotech firm. This success is viewed as a pivotal step toward potential regulatory approval and future commercialization of the therapy.